Helius Total Stockholder Equity vs Deferred Long Term Liab Analysis
HSDT Stock | USD 0.45 0.02 4.65% |
Helius Medical financial indicator trend analysis is much more than just examining Helius Medical Techn latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Helius Medical Techn is a good investment. Please check the relationship between Helius Medical Total Stockholder Equity and its Deferred Long Term Liab accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Helius Medical Technologies. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.
Total Stockholder Equity vs Deferred Long Term Liab
Total Stockholder Equity vs Deferred Long Term Liab Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Helius Medical Techn Total Stockholder Equity account and Deferred Long Term Liab. At this time, the significance of the direction appears to have very week relationship.
The correlation between Helius Medical's Total Stockholder Equity and Deferred Long Term Liab is 0.24. Overlapping area represents the amount of variation of Total Stockholder Equity that can explain the historical movement of Deferred Long Term Liab in the same time period over historical financial statements of Helius Medical Technologies, assuming nothing else is changed. The correlation between historical values of Helius Medical's Total Stockholder Equity and Deferred Long Term Liab is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Stockholder Equity of Helius Medical Technologies are associated (or correlated) with its Deferred Long Term Liab. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Deferred Long Term Liab has no effect on the direction of Total Stockholder Equity i.e., Helius Medical's Total Stockholder Equity and Deferred Long Term Liab go up and down completely randomly.
Correlation Coefficient | 0.24 |
Relationship Direction | Positive |
Relationship Strength | Very Weak |
Total Stockholder Equity
The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.Deferred Long Term Liab
Liabilities that are due after more than one year, including deferred tax liabilities and deferred revenue.Most indicators from Helius Medical's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Helius Medical Techn current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Helius Medical Technologies. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. At this time, Helius Medical's Selling General Administrative is comparatively stable compared to the past year. Enterprise Value Over EBITDA is likely to gain to 0.02 in 2024, despite the fact that Enterprise Value is likely to grow to (225.7 K).
Helius Medical fundamental ratios Correlations
Click cells to compare fundamentals
Helius Medical Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Helius Medical fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Common Stock Shares Outstanding | 15.1K | 24.0K | 49.1K | 269.9K | 607.9K | 577.5K | |
Total Assets | 10.3M | 6.5M | 14.1M | 17.3M | 7.7M | 9.9M | |
Total Current Liabilities | 3.8M | 2.4M | 2.7M | 2.0M | 1.9M | 1.8M | |
Total Stockholder Equity | 5.8M | 3.9M | 11.3M | 8.2M | 2.4M | 2.9M | |
Net Tangible Assets | 4.0M | 3.9M | 10.2M | 8.0M | 9.2M | 9.7M | |
Net Debt | (4.8M) | (3.2M) | (11.0M) | (14.4M) | (5.1M) | (5.4M) | |
Retained Earnings | (104.8M) | (118.9M) | (137.0M) | (151.1M) | (160.0M) | (152.0M) | |
Accounts Payable | 1.7M | 747K | 1.1M | 627K | 531K | 504.5K | |
Cash | 5.5M | 3.3M | 11.0M | 14.5M | 5.2M | 7.6M | |
Cash And Short Term Investments | 5.5M | 3.3M | 11.0M | 14.5M | 5.2M | 7.7M | |
Common Stock Total Equity | 52.2M | 26K | 31K | 1K | 900.0 | 855.0 | |
Liabilities And Stockholders Equity | 10.3M | 6.5M | 14.1M | 17.3M | 7.7M | 9.9M | |
Other Current Assets | 610K | 735K | 862K | 1.2M | 1.0M | 777.2K | |
Total Liab | 4.5M | 2.7M | 2.8M | 9.1M | 5.3M | 7.1M | |
Total Current Assets | 7.2M | 4.7M | 12.6M | 16.7M | 7.4M | 9.1M | |
Short Term Debt | 172K | 118K | 6K | 108K | 90K | 85.5K | |
Common Stock | 26K | 31K | 1K | 4K | 28K | 950.0 | |
Other Current Liab | 1.5M | 1.3M | 1.2M | 1.2M | 1.0M | 994.7K | |
Net Receivables | 574K | 230K | 251K | 343K | 637K | 401.2K | |
Non Current Liabilities Total | 710K | 252K | 193K | 7.1M | 3.5M | 2.6M | |
Capital Surpluse | 6.6M | 105.4M | 111.5M | 123.9M | 142.5M | 149.6M | |
Other Stockholder Equity | 111.5M | 123.9M | 149.4M | 159.6M | 163.0M | 91.3M | |
Accumulated Other Comprehensive Income | (902K) | (1.1M) | (1.1M) | (388K) | (673K) | (706.7K) | |
Non Current Assets Total | 3.1M | 1.9M | 1.5M | 590K | 254K | 241.3K | |
Property Plant And Equipment Net | 1.3M | 576K | 412K | 450K | 230K | 418.2K | |
Net Invested Capital | 5.8M | 3.9M | 11.3M | 8.2M | 2.4M | 2.2M | |
Property Plant And Equipment Gross | 1.3M | 576K | 412K | 450K | 589K | 631.4K | |
Net Working Capital | 3.4M | 2.3M | 9.9M | 14.7M | 5.6M | 5.8M | |
Property Plant Equipment | 1.3M | 486K | 412K | 450K | 517.5K | 612.2K | |
Inventory | 598K | 389K | 476K | 589K | 457K | 531.9K |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Helius Stock Analysis
When running Helius Medical's price analysis, check to measure Helius Medical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Helius Medical is operating at the current time. Most of Helius Medical's value examination focuses on studying past and present price action to predict the probability of Helius Medical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Helius Medical's price. Additionally, you may evaluate how the addition of Helius Medical to your portfolios can decrease your overall portfolio volatility.